Atara Biotherapeutics (ATRA) Accumulated Depreciation & Amortization (2022 - 2025)
Atara Biotherapeutics (ATRA) has disclosed Accumulated Depreciation & Amortization for 4 consecutive years, with $375000.0 as the latest value for Q2 2025.
- For the quarter ending Q2 2025, Accumulated Depreciation & Amortization changed N/A year-over-year to $375000.0, compared with a TTM value of $375000.0 through Jun 2025, changed N/A, and an annual FY2024 reading of $17.3 million, up 9.06% over the prior year.
- Accumulated Depreciation & Amortization was $375000.0 for Q2 2025 at Atara Biotherapeutics, down from $1.7 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $18.0 million in Q3 2024 and bottomed at $375000.0 in Q2 2025.
- Average Accumulated Depreciation & Amortization over 4 years is $11.3 million, with a median of $13.3 million recorded in 2023.
- The sharpest move saw Accumulated Depreciation & Amortization increased 27.75% in 2023, then grew 9.06% in 2024.
- Year by year, Accumulated Depreciation & Amortization stood at $12.4 million in 2022, then rose by 27.75% to $15.9 million in 2023, then grew by 9.06% to $17.3 million in 2024, then crashed by 97.83% to $375000.0 in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for ATRA at $375000.0 in Q2 2025, $1.7 million in Q1 2025, and $17.3 million in Q4 2024.